Amgen Inc.
Amgen Inc. AMGN Peers
See (AMGN) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMGN | $262.28 | -3.02% | 141.03B | 23.89 | $10.98 | +3.48% |
| LLY | $715.48 | -4.10% | 678.09B | 58.12 | $12.31 | +0.75% |
| AZN | $66.23 | -2.20% | 410.68B | 26.71 | $2.48 | +2.32% |
| JNJ | $146.32 | -1.43% | 352.61B | 16.26 | $9.00 | +3.39% |
| ABBV | $177.44 | -5.62% | 313.43B | 76.15 | $2.33 | +3.59% |
| NVO | $64.38 | -1.56% | 285.31B | 18.24 | $3.53 | +2.50% |
| NVS | $104.94 | -1.77% | 207.27B | 16.45 | $6.38 | +3.78% |
| MRK | $73.50 | -4.08% | 184.56B | 10.68 | $6.88 | +4.28% |
| PFE | $22.00 | -3.83% | 125.05B | 15.94 | $1.38 | +7.69% |
| GILD | $98.38 | -3.01% | 122.38B | 12.71 | $7.74 | +3.15% |
Stock Comparison
AMGN vs LLY Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, LLY has a market cap of 678.09B. Regarding current trading prices, AMGN is priced at $262.28, while LLY trades at $715.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas LLY's P/E ratio is 58.12. In terms of profitability, AMGN's ROE is +0.93%, compared to LLY's ROE of +0.77%. Regarding short-term risk, AMGN is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs AZN Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, AZN has a market cap of 410.68B. Regarding current trading prices, AMGN is priced at $262.28, while AZN trades at $66.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas AZN's P/E ratio is 26.71. In terms of profitability, AMGN's ROE is +0.93%, compared to AZN's ROE of +0.19%. Regarding short-term risk, AMGN is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs JNJ Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, JNJ has a market cap of 352.61B. Regarding current trading prices, AMGN is priced at $262.28, while JNJ trades at $146.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas JNJ's P/E ratio is 16.26. In terms of profitability, AMGN's ROE is +0.93%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, AMGN is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs ABBV Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, ABBV has a market cap of 313.43B. Regarding current trading prices, AMGN is priced at $262.28, while ABBV trades at $177.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas ABBV's P/E ratio is 76.15. In terms of profitability, AMGN's ROE is +0.93%, compared to ABBV's ROE of +0.70%. Regarding short-term risk, AMGN is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs NVO Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, NVO has a market cap of 285.31B. Regarding current trading prices, AMGN is priced at $262.28, while NVO trades at $64.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas NVO's P/E ratio is 18.24. In terms of profitability, AMGN's ROE is +0.93%, compared to NVO's ROE of +0.81%. Regarding short-term risk, AMGN is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs NVS Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, NVS has a market cap of 207.27B. Regarding current trading prices, AMGN is priced at $262.28, while NVS trades at $104.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas NVS's P/E ratio is 16.45. In terms of profitability, AMGN's ROE is +0.93%, compared to NVS's ROE of +0.31%. Regarding short-term risk, AMGN is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs MRK Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, MRK has a market cap of 184.56B. Regarding current trading prices, AMGN is priced at $262.28, while MRK trades at $73.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas MRK's P/E ratio is 10.68. In terms of profitability, AMGN's ROE is +0.93%, compared to MRK's ROE of +0.38%. Regarding short-term risk, AMGN is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs PFE Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, PFE has a market cap of 125.05B. Regarding current trading prices, AMGN is priced at $262.28, while PFE trades at $22.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas PFE's P/E ratio is 15.94. In terms of profitability, AMGN's ROE is +0.93%, compared to PFE's ROE of +0.09%. Regarding short-term risk, AMGN is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs GILD Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, GILD has a market cap of 122.38B. Regarding current trading prices, AMGN is priced at $262.28, while GILD trades at $98.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas GILD's P/E ratio is 12.71. In terms of profitability, AMGN's ROE is +0.93%, compared to GILD's ROE of +0.32%. Regarding short-term risk, AMGN is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs CELG-RI Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, CELG-RI has a market cap of 120.38B. Regarding current trading prices, AMGN is priced at $262.28, while CELG-RI trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.93%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, AMGN is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs SNY Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, SNY has a market cap of 120.34B. Regarding current trading prices, AMGN is priced at $262.28, while SNY trades at $49.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas SNY's P/E ratio is 17.58. In terms of profitability, AMGN's ROE is +0.93%, compared to SNY's ROE of +0.08%. Regarding short-term risk, AMGN is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs BMY Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, BMY has a market cap of 89.77B. Regarding current trading prices, AMGN is priced at $262.28, while BMY trades at $44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas BMY's P/E ratio is 16.46. In terms of profitability, AMGN's ROE is +0.93%, compared to BMY's ROE of +0.32%. Regarding short-term risk, AMGN is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs GSK Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, GSK has a market cap of 73.61B. Regarding current trading prices, AMGN is priced at $262.28, while GSK trades at $36.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas GSK's P/E ratio is 17.85. In terms of profitability, AMGN's ROE is +0.93%, compared to GSK's ROE of +0.22%. Regarding short-term risk, AMGN is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs HZNP Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, HZNP has a market cap of 26.60B. Regarding current trading prices, AMGN is priced at $262.28, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AMGN's ROE is +0.93%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AMGN is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs BIIB Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, BIIB has a market cap of 17.64B. Regarding current trading prices, AMGN is priced at $262.28, while BIIB trades at $120.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas BIIB's P/E ratio is 11.89. In terms of profitability, AMGN's ROE is +0.93%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, AMGN is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs GRFS Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, GRFS has a market cap of 5.93B. Regarding current trading prices, AMGN is priced at $262.28, while GRFS trades at $7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas GRFS's P/E ratio is 29.12. In terms of profitability, AMGN's ROE is +0.93%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, AMGN is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs OGN Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, OGN has a market cap of 2.09B. Regarding current trading prices, AMGN is priced at $262.28, while OGN trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas OGN's P/E ratio is 2.79. In terms of profitability, AMGN's ROE is +0.93%, compared to OGN's ROE of +1.82%. Regarding short-term risk, AMGN is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs CTOR Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, CTOR has a market cap of 63.70M. Regarding current trading prices, AMGN is priced at $262.28, while CTOR trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas CTOR's P/E ratio is -2.62. In terms of profitability, AMGN's ROE is +0.93%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, AMGN is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs SCLX Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, SCLX has a market cap of 31.03M. Regarding current trading prices, AMGN is priced at $262.28, while SCLX trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas SCLX's P/E ratio is -0.21. In terms of profitability, AMGN's ROE is +0.93%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, AMGN is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs SCLXW Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, SCLXW has a market cap of 29.28M. Regarding current trading prices, AMGN is priced at $262.28, while SCLXW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.93%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, AMGN is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs MIRA Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, MIRA has a market cap of 22.36M. Regarding current trading prices, AMGN is priced at $262.28, while MIRA trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas MIRA's P/E ratio is -2.61. In terms of profitability, AMGN's ROE is +0.93%, compared to MIRA's ROE of -2.82%. Regarding short-term risk, AMGN is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs SRXH Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 141.03B. In comparison, SRXH has a market cap of 11.15M. Regarding current trading prices, AMGN is priced at $262.28, while SRXH trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 23.89, whereas SRXH's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.93%, compared to SRXH's ROE of N/A. Regarding short-term risk, AMGN is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.